Rachel Davis

Johnson University, Rutgers, The State University of New Jersey

Papers

Total Citations

H-Index

About

Rachel Davis’s research focuses on urologic oncology, with key contributions in prostate and bladder cancer management. Her most cited work, “Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer” (2015, 50 citations), introduced a novel, accessible method using routine blood tests to better risk-stratify patients—potentially reducing unnecessary biopsies or overtreatment. This study has become a reference point for integrating inflammatory biomarkers into prostate cancer decision-making. Davis also contributed to the surgical literature with her 2016 paper comparing open versus robotic cystectomy for muscle-invasive bladder cancer, providing timely outcome data as robotic-assisted radical cystectomy (RARC) adoption grows. By evaluating perioperative and oncologic endpoints, her work helps guide surgeons and patients in choosing between the gold-standard open approach and emerging minimally invasive techniques. Though her citation counts are modest, Davis’s research addresses practical clinical dilemmas—improving risk stratification and informing surgical choices—making her contributions valuable for urologists seeking evidence-based, patient-centered care.